This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Bradbury has joined the company''s board. Bradbury is a member of life sciences consulting and investment firm BioBrit LLC; he also served as President and CEO of Amylin Pharmaceuticals. The company said the funding primarily came from high net worth individuals. As part of the funding, Daniel M. READ MORE>>.
According to Alume, the funding came from angel investors, including co-founder Chrysa Mineo (formerly of Receptos and Neurocrine Biosciences) and Dan Bradbury (co-founder and Executive Chairman of Equillium, Inc. La Jolla-based biotechnology startup Alume Biosciences announced that it has raised $5.5M and former CEO of Amylin).
As part of the funding Dan Bradbury, the former CEO of Amylin Pharmaceuticals, has joined as executive chairman, and M Ventures' Edwards Kliphuis, along with Hikma Ventures' Lana Ghanem have both joined the company's board. Biolinq is led by CEO Jared Tangney.
Headed by former Amylin CEO Dan Bradbury, Equillium (NASDAQ: EQ ) has licensed the drug, itolizumab, which it calls EQ001, from Indian pharma giant Biocon Limited for development in the United States and Canada. Equillium was formed to advance.
Bradbury, former CEO of Amylin Pharmacueticals, as a new Chairman of its board, and also added Sherman Atkinson as a Director of the company with the funding. The company said it has added Daniel M. READ MORE>>. liquidgrids liquid grids venture capital healthcare marketing advertising'
Tom Bradbury. Moms shrieked. Five or so minutes later, the kid would swim to Tom. Then again and again and that was it. He was swimming! Here’s a great piece on the infamous [Swim to.] For the next few months, if my son acted up, a simple “I’m calling Tom” would get him immediately in line.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content